drugset / Trial / NCT00970229

Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.

NCT00970229 ↗

Phase 1 Completed 19 enrolled Institute for Neurodegenerative Disorders
NaSingle-groupOpen-labelDiagnostic

Summary

The underlying goal of this study is to assess \[123I\]MNI-420 SPECT imaging as a tool to detect A2aR density in the brain of PD and HD research participants to be compared with similarly aged healthy subjects.

Timeline

Start
2009-07
Primary completion
2015-04
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject [123I]MNI-420 Unknown 296 mbq —